Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Exclusion Criteria

• •1. No more than a total of 15 headache days per month.
• •2. Use of more than 2 migraine preventive medications.
• •3. Current diagnosis of glaucoma.
• •4. Use of opioids or barbiturates more than 4 days/month, triptans or ergots 10 or more days/month, or simple analgesics (e.g., aspirin, NSAIDs, acetaminophen) 15 or more days/month in the 3 months prior to Visit 1.
• •5. Current diagnosis of any post-traumatic headaches, medication overuse headaches, new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), painful cranial neuropathy or daily headaches.
• •6. Vaccination within less than 7 days from the Screening or plans to get a vaccine during the study or within a week after final study dose.